Kinase inhibitors: The next generation of therapies in the treatment of rheumatoid arthritis
Authors:
- 27 January 2014
- journal article
- review article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 17 (4) , 359-368
Abstract
Rheumatoid arthritis (RA) can be the source of significant pain and functional limitation. The past 20 years have seen a transition in treatment goals away from mere pain management toward disease modification through the suppression of autoimmunity. Disease‐modifying anti‐rheumatic drugs, such as methotrexate and biologic agents, impair disease progression and joint destruction. However, despite these achievements, a substantial subset ofRApatients does not respond to or cannot tolerate current treatments forRA. Scientific insight into the cellular pathways of inflammation has revealed new therapeutic targets for the treatment of autoimmune diseases likeRA. Attention has focused on pathways mediated by Janus kinase (JAK), mitogen‐activated protein kinase (MAPK), and spleen tyrosine kinase (Syk). This review article summarizes the evidence supporting the use of various kinase inhibitors, including the newly approvedJAKinhibitor tofacitinib, in the treatment ofRA.Keywords
This publication has 45 references indexed in Scilit:
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trialThe Lancet, 2013
- Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic studyArthritis & Rheumatism, 2013
- Jakinibs: a new class of kinase inhibitors in cancer and autoimmune diseaseCurrent Opinion in Pharmacology, 2012
- The many faces of Janus kinaseBiochemical Pharmacology, 2012
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- Inborn Errors of Human JAKs and STATsImmunity, 2012
- Measurement and Rates of Persistence With and Adherence to Biologics for Rheumatoid Arthritis: A Systematic ReviewClinical Therapeutics, 2011
- Joint inflammation and cytokine inhibition in rheumatoid arthritisClinical and Experimental Medicine, 2006
- Evolving concepts of rheumatoid arthritisNature, 2003
- Efficacy of Low-Dose Methotrexate in Rheumatoid ArthritisNew England Journal of Medicine, 1985